1357072-61-7
1357072-61-7
Chemical Structure
c-Met inhibitor 1
- CAS No.: 1357072-61-7
- Formula:C17H14N8S
- Molecular Weight:362.41
IUPAC Name: 6-(1-methyl-1H-pyrazol-4-yl)-3-((2-methyl-2H-indazol-5-yl)thio)-[1,2,4]triazolo[4,3-b]pyridazine
InChIKey: JYXHZDNTBJUJNH-UHFFFAOYSA-N
SMILES: CN1N=CC(C2=NN3C(C=C2)=NN=C3SC4=CC5=CN(C)N=C5C=C4)=C1
Biological Activity: c-Met inhibitor 1 is an orally active c-Met inhibitor. c-Met inhibitor 1 can inhibit c-Met phosphorylation with an IC50 of 0.010 μM. c-Met inhibitor 1 has antitumor activity and can be used for the research of tumors such as gastric cancer, pancreatic cancer and malignant glioma[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
c-Met inhibitor 1 | 98.89% | c-Met inhibitor 1 is an orally active c-Met inhibitor. c-Met inhibitor 1 can inhibit c-Met phosphorylation with an IC50 of 0.010 μM. c-Met inhibitor 1 has antitumor activity and can be used for the research of tumors such as gastric cancer, pancreatic cancer and malignant glioma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
JNJ-38877618 | 98.85% | JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SGX-523 | 99.51% | SGX523 is a exquisitely selective and ATP-competitive MET inhibitor. SGX523 potently inhibits MET with an IC50 of 4 nM and is >1,000-fold selective versus other protein kinases. Antitumor activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AMG-208 | 99.86% | AMG-208 is an orally active c-Met/RON dual selective inhibitor with an IC50 of 9 nM for c-Met. AMG-208 is a CYP3A4 inhibitor with an IC50 of 32 μM. AMG-208 has anti-cancer activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bozitinib | 98.88% | Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PF-06371900 | 99.43% | PF-06371900 is a potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PF 04254644 | PF 04254644 is an orally active c-Met inhibitor. PF 04254644 inhibits mesenchymal transfer factor/hepatocyte growth factor receptor. PF 04254644 induces myocardial degeneration in rats. PF 04254644 may be used in research on cardiovascular disease and cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NVP-BVU972 | 98.78% | NVP-BVU972 is an selective and potent Met inhibitor, with an IC50 of 14 nM. NVP-BVU972 also exhibits good anti-proliferative activity against Met with drug-resistant mutations and inhibits phosphorylation. NVP-BVU972 can be used in study of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MAP3K1-IN negative control | ||||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
JNJ-38877605 | 99.95% | JNJ-38877605 is an orally active ATP-competitive inhibitor of c-Met with an IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
JNJ-38877605-d1 | JNJ-38877605-d1 (compound DO-2) is a highly selective MNNG HOS transforming (MET) inhibitor. JNJ-38877605-d1 is thought to diminish the formation of the Aldehyde Oxidase 1 inactive metabolite M3. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
